ASGR2
Asialoglycoprotein receptor 2
As of the edition of 20 October 2026, ASGR2 (asialoglycoprotein receptor 2, UniProt P07307) has 3 drugs tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07307
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Nutrition and metabolism; Heart and blood vessels
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lumasiran | Marketed | Phase 3 | Ends 2038 |
| Nedosiran sodium | Marketed | Phase 3 | Ends 2038 |
| Nedosiran | Marketed | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Alnylam Pharmaceuticals | Route B |
| Novo Nordisk | Route B |
The other 0 companies at ASGR2
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at ASGR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.